A comprehensive view of Bausch & Lomb Inc.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.
Emergent BioSolutions appoints Joseph C. Papa as president and CEO, succeeding interim CEO Haywood Miller from February 21, 2024; Papa previously served as CEO and Chairman at Bausch and Lomb Corporation
Published:
February 22, 2024
by Executive Appointments Monitor Worldwide
|
Bausch + Lomb introduces surgical planning software for Eyetelligence platform to streamline surgical planning and information flow; software integrates with electronic medical records and diagnostic devices, eliminating need for specific equipment
Published:
October 26, 2023
by Contify Life Science News
|
Bausch Health and its dermatology business, Ortho Dermatologics, announce FDA approval for Cabtreo Topical Gel 1.2%/0.15%/3.1%, for the topical treatment of acne vulgaris in patients twelve years of age and older
Published:
October 23, 2023
by ENP Newswire
|
Bausch + Lomb debuts Lumify Eye Illuminations in the US, a new line of hypoallergenic specialty products for the eye area; line includes 3-in-1 Micellar Cleansing Water and Eye Makeup Remover, Nourishing Lash & Brow Serum, Hydra-Gel Brightening Eye Cream
Published:
October 06, 2023
by Bausch & Lomb Inc.
|
Novartis completes divestment of front of eye ophthalmology assets to Bausch + Lomb for US$1.75B in upfront cash; assets include dry eye disease prescription drug Xiidra and SAF312 libvatrep, currently under development for chronic ocular surface pain
Published:
October 02, 2023
by ENP Newswire
|
Ask us about our Health Care Sector market view